Competitive Product Potential
TRT’s proprietary mesenchymal stem cell platform is a strategically valuable asset with a broad range of applicability: regenerative medicine therapeutics, immune inflammatory diseases and biopharmaceutical therapies. Additionally HUCPVCs
are the richest, most inexhaustible source of MSCs ever described.
Proprietary Harvesting Technology
The TRT technology is based on the following characteristics:
- Broad international patent protection in all major markets
- Easily harvested source from medical waste
- Cells more biologically potent (more therapeutically useful) than MSCs derived from adult tissue (whole human genome data to confirm)
Strong Market Expansion Potential
TRT already contributes its products to the research and family banking markets as well as biopharmaceutical applications such as biodefence. However, to utilize this rich MSC source to its fullest potential we constantly seek collaborative opportunities to further develop HUCPVC applications in biopharmaceutical, cell therapeutics and regenerative medicine sectors.